Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study

NCT04697160 is registered in ClinicalTrials.gov with MorphoSys AG as lead sponsor.

NCT NCT04697160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study
Lead sponsor
MorphoSys AG
Phase
Observational
Overall status
Completed
Start date
April 1, 2020
Completion date
May 7, 2021
Enrollment
3,573 (actual)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma